Dulaglutide is cardioprotective with or without background metformin in patients with diabetes and established or high risk for coronary vascular disease. A subgroup analysis of the REWIND Trial.
29 August 2020 (00:00 - 00:00)
Organised by:
About the speaker
Karolinska Institute, Stockholm (Sweden)
7 More presentations in this session
Professor H. Colhoun (Edinburgh, GB)
Doctor H. Kondo (Yufu City, JP)
Access the full session
The Event
ESC Congress 2020
29 August - 1 September 2020
You may be interested in
Congress Presentation
Congress Presentation
Congress Presentation
